Pitavastatin Magnesium

匹伐他汀镁

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NamePitavastatin Magnesium
Drug Alias NameZypitamag
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHMG-CoA reductase inhibitors
TargetsHMG-CoA reductase
Therapy Area/IndicationsHypercholesterolemiaHyperlipidemiasDyslipidemias +[8] 
Global Approved IndicationsHyperlipidemiasDyslipidemias
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/07/14
Country/TerritoryCanadaBotswanaUnited States +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesZydus Cadila
China Registration ClassN/A

Develop Information

Active CompaniesMedicure IncNational Institute On Aging (NIA)National Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesHanmi Pharmaceutical Co LtdKowa Research Europe LtdTai Tien Pharmaceuticals Co Ltd +[5] 
Active IndicationsHyperlipidemiasDyslipidemiasCardiovascular Diseases +[4] 
Inactive IndicationsHypercholesterolemiaMetabolic SyndromeDiabetes Mellitus, Type 2 +[4] 

Other Information

ATC CodeC10AA08
Related LinksWikipediaDrugBank